Effect of Led Therapy (630 ± 20nm) in Herpes Simplex Labial
- Conditions
- Herpes simplexherpes labialisC02.256.466.382C02.256.466.382.316
- Registration Number
- RBR-56f4w8
- Lead Sponsor
- niversidade do Vale do Paraiba UNIVAP
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
age between 18 and 59 years old, Caucasian, first manifestation of the disease, history of cold sores and / or presented the lesion, healthy individual without comorbidities, agree and sign the Informed Consent Form, after clarifying the research.
presence of neoplastic lesions in the oral environment; HSV-2 lesion in the genitalia; belonging to the Fitzpatrick V and VI classification scale; pregnant or lactating women; hypersensitivity to any component in the acyclovir formula; liver or kidney problems against acyclovir indication ; intraoral herpes; For ethical reasons excluded volunteers received conventional treatment guidance.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome 1: Reduce disease onset time, number of recurrences, size of lesions, in the control period of five months after treatment. Checking by means of the patient's evaluation method with visual analog scale EVA, signs and symptoms lesion evaluation form and photographic control. From the observation of a variation of at least 5% in the pre and post-intervention measurements.;Expected outcome 1: Groups treated with low-level laser therapy have a higher performance compared to groups treated with conventional medication and control.
- Secondary Outcome Measures
Name Time Method Outcome found 1: Groups treated with conventional medication and control, presented slower repair times, recurrences in the control period, lesion size without decrease when recurrent. Groups treated with low-level laser therapy showed faster repair time and did not experience recurrences in the control period, five months.